NVO has seen a significant decrease of 60% over the past year. Despite this downturn, insiders are purchasing stock, including a recent purchase of 2350 shares by a board member. A new CEO, who is perceived as more serious, has lowered guidance, a common strategy for new leadership to facilitate future earnings beats. Catalysts for a potential turnaround include positive developments like US approval for WeGovy for liver disease treatment (MASH), potentially opening new markets. Also expects oral GLP-1 may get an FDA decision, is coming, and it has been revealed that NVO will get it before LLY, which is planned for Q4. The company has lowered the price of Ozempic by 50% to $500 a month through telehealth partnerships. NVO possesses solid patent protection expiring no sooner than 2031, and holds a market share of the weight-loss market. The stock is currently trading around 14 times earnings.